What eHCPs think about 2024 clinical trials for pharmaceuticals and digital therapeutic tools

13.02.2024 | Insight

What eHCPs think about 2024 clinical trials for pharmaceuticals and digital therapeutic tools

On 7 December 2023, Nature Medicine published a yearly review entitled “11 clinical trials that will shape medicine in 2024”. Among the 11 clinical trials discussed, three are in Phase 2 or higher and have already published results, with the rest are still in early stages. Most of the clinical trials were focused on pharmaceuticals, however, a few were assessing digital tools for medicinal purposes, including artificial intelligence. CREATION.co analysed how online healthcare professionals (eHCPs) responded to these trials last year. 

eHCPs are eagerly anticipating the new malaria vaccine

Clinicians in the University of Oxford and Serum Institute of India are midway through a phase III trial of the R21/Matrix-M vaccine against clinical malaria in African children. This trial is coming to an end, and vaccines are likely to be rolled out worldwide soon, eHCPs have already expressed their enthusiasm about the vaccine being approved in Ghana and emphasised the importance of the vaccine, mentioning its efficacy and cost-effectiveness. eHCPs brought their personal stories around the need for the vaccine.

According to eHCPs, the NADINA trial is shaping the melanoma space

The NADINA trial, taking place in the The Netherlands Cancer Institute, is an international phase III trial that aims to compare the efficacy of neoadjuvant ipilimumab plus nivolumab with that of standard adjuvant nivolumab in macroscopic stage III melanoma. 44 eHCPs shared the initial results of the trial with their peers which were presented at AACR 2023. eHCPs congratulated the different institutes that collaborated on this study and the research teams. Professor Georgina Long, who was part of the research team, commented on how proud they are to be part of this study and mentioned there was more work to do. Dr Jason Luke described the results as field-changing and felt that NADINA is a “hugely important study”, in a post shared 20 times by his peers.

The VERVE-101 trial uses leading-edge technology for hypercholesterolemia

During the American Heart Association Conference various cardiovascular trials were presented, giving the opportunity to eHCPs to share their thoughts. One of those trials was VERVE-101, by Verve Therapeutics, a novel CRISPR base editor tool designed to alter the genetic code of patients with familial hypercholesterolemia and cardiovascular disease. 

Dr Ritu Thamman described the trial outcomes as a scientific milestone and congratulated Verve Therapeutics for their achievement. Some eHCPs expressed an interest in hearing more about the trial and most were positive about the results of VERVE-101. In addition, 56 eHCPs shared Sek Kathiresan’s post, CEO of Verve, who applauded the trial as a scientific innovation. However, seven eHCPs shared Venk Murthy’s post expressing concerns about certain cardiac complications that occurred during the study and suggested that the study should terminate earlier than planned.

The STEM-PD trial receives support from eHCPs

A leading Parkinson’s therapy involves transplanting dopamine-producing cells into the brain, which could offer a breakthrough in repairing the damage. The STEM-PD trial, by the Skane University Hospital, studies the effect of implanting dopaminergic neurons from human embryonic stem cells in patients with moderate Parkinson’s disease. eHCPs were filled with hope by the potential of this trial as they shared updates online. They described this trial as a “milestone trial” after the first patient successfully received the transplant. eHCPs discussed the treatment as a breakthrough in Parkinson’s space and congratulated the medical team for their landmark contribution.

Although in the early stages, the VIR-1338 HIV vaccine trial is receiving positive reactions from eHCPs

A preventative HIV vaccine is an ongoing pursuit in the scientific community to protect individuals and communities from the virus. The VIR-1338 trial, by Vir Biotechnology Inc., is testing a novel vaccine that induces an HIV immune response in people. eHCPs were delighted to receive the news that the trial has begun enrollment in the US and South Africa. Of the 110 eHCPs who shared the Nature article, 30 chose to highlight the HIV vaccine trial to comment on.

Related content

https://creation.co/knowledge/how-ehcps-responded-to-the-hiv-landscape-in-2023/

https://creation.co/knowledge/how-ehcps-can-influence-the-hiv-epidemic-in-south-america/

—————————————

Digital therapeutic and AI tools emerge 

The ascent of digital therapeutics marks a transformative shift in healthcare, employing innovative technologies for evidence-based interventions. From mental health apps to wearable devices, these innovations empower individuals, offering personalised solutions. As regulatory support grows, the integration of digital therapeutics promises a more accessible and patient-centric era in healthcare.

Among a variety of digital tools currently being developed, Nature’s list included a few, including a particular AI tool for lung cancer detection. 

Early detection of lung cancer is crucial for saving lives, yet it is often diagnosed at advanced stages. Aiming to expedite diagnosis and improve outcomes, an ongoing trial in six UK hospitals involves applying artificial intelligence to chest X-rays immediately upon capture. The study examines whether this AI intervention shortens the time of a patient receiving a CT scan. A few eHCPs shared this clinical trial with their peers and showcased curiosity by sharing Qure.AI’s posts, the company that manufactures the digital tool, eHCPs discussed the trial by sharing a post mentioning that it could save thousands of lives every year. eHCPs also shared posts from an NHS social media account, discussing the AI technology and the potential it has for reducing treatment delays.

Stay up to date with HCPs’ views

As research keeps progressing, clinical trials will populate and forever alter every aspect of medicine and human health for the better. Moving forward into the digital era, more and more clinical trials may access treatments based on technology and artificial intelligence. 

CREATION.co publishes monthly updates on pharmaceutical approvals and is bringing insights on what eHCPs across the globe think around the latest product launches.

If you would like to find out more about this research or connect with your healthcare professional stakeholders in a meaningful way then do not hesitate to get in touch as we’d love to hear from you and share more examples with you.

Share this article

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next


02.06.2023 | Article

Product Launch Tracker: eHCPs are delighted with the approval of the first RSV vaccine for adults aged 60 and over.

Discover which new drug approvals HCPs are talking about

10.11.2023 | Article

EASD 2023: what drove online conversation among HCPs and people with diabetes?

There were hundreds of presentations, posters and spotlight talks over the five days

By Jamie Doggett

View all articles >